 Home > Biochemical Engineering > Polypeptide > Retatrutide for Sale > Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide

Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide buy - large image1

Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide buy - image1

Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide buy - image2

Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide

TDS 7494 Inquiries

Unit Price:

$47-60/UNIT FOB

Get Latest Price 

CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99.9%

Port:

Guangdong

Packaging:

5mg/10vials,10vials/box

Price valid (until):

2027-01-08

 The product will be displayed normally on the website later.

HONG KONG BURSON POLYPEPTIDE R&D LIMITED

Company Type:

Trader

Location:

Hongkong, China

Qualification:

Main Products:

Tirzepatide,Retatrutide,Semaglutide,GHK-Cu

 Visit Store

Product Details
Seller Information
Inquiry History

Description

Peptide

Retatrutide (LY3437943) is an innovative, research-grade triple agonist peptide designed to support advanced metabolic studies and body composition management. As a single-molecule compound that simultaneously targets and activates three key metabolic receptors—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors—it represents a significant evolution in peptide research, building on the foundation of earlier molecules while delivering a more comprehensive and synergistic mechanism of action. This unique triple-receptor activation profile distinguishes Retatrutide from other peptides in its class, making it a leading choice for research focused on metabolic regulation, weight management, and related physiological pathways.

At the molecular level, Retatrutide is engineered with a peptide backbone structure that enhances its binding affinity and agonistic activity at all three target receptors, ensuring balanced and potent activation across each pathway. The compound is formulated as a sterile, lyophilized (freeze-dried) white powder, packaged in sealed vials to preserve stability and purity. Each batch is manufactured under strict quality control standards, with a minimum purity of 99% verified by HPLC-MS (High-Performance Liquid Chromatography-Mass Spectrometry), and accompanied by a batch-specific Certificate of Analysis (COA) for full transparency and traceability. The formulation is stable for up to 36 months when stored at -20°C, with consistent potency and performance maintained throughout the shelf life, making it suitable for long-term research applications.

The mechanism of action of Retatrutide is defined by the synergistic activation of GLP-1, GIP, and glucagon receptors, each contributing distinct and complementary effects to support metabolic health and body composition goals. Activation of the GLP-1 receptor primarily influences appetite regulation and gastric function: it slows gastric emptying, which promotes prolonged feelings of satiety and reduces overall food intake by modulating central nervous system pathways that control hunger and cravings. Additionally, GLP-1 receptor activation enhances glucose-dependent insulin secretion from pancreatic beta cells, supporting healthy blood glucose metabolism and insulin sensitivity.

GIP receptor activation works in tandem with GLP-1 to amplify metabolic benefits. It enhances insulin secretion in response to nutrient intake, improves glucose tolerance, and supports adipocyte metabolic flexibility, which aids in the efficient breakdown and utilization of fat tissue. This pathway also complements GLP-1 activity by promoting gastrointestinal tolerability, reducing the likelihood of adverse digestive effects often associated with single-receptor agonists.

Glucagon receptor activation, the third key component of Retatrutide’s action, drives increased energy expenditure and enhanced lipolysis (fat breakdown). It stimulates hepatic lipid mobilization, reduces lipogenesis (fat storage), and promotes the oxidation of fat tissue for energy, making it a critical driver of fat loss and improvements in body composition. Importantly, the mild hyperglycemic effect of glucagon is balanced and neutralized by the glucose-lowering actions of GLP-1 and GIP receptors, ensuring overall metabolic balance and safety.

In research studies, Retatrutide has demonstrated remarkable efficacy in supporting weight management and metabolic health, with results that surpass many single or dual-receptor agonist peptides. In clinical research trials, participants using Retatrutide have achieved significant, dose-dependent reductions in body weight, with the highest dose groups showing average weight loss of up to 17.5% at 24 weeks and 26.2% at 48 weeks, far exceeding outcomes observed with older peptides. Notably, the weight loss achieved with Retatrutide is predominantly fat tissue—approximately 83% of lost weight is fat—while preserving lean muscle mass. This preservation of muscle is essential for maintaining healthy basal metabolic rate, avoiding the muscle loss often associated with traditional weight management approaches, and supporting long-term metabolic health.

Beyond weight management, Retatrutide research has highlighted its beneficial effects on multiple metabolic markers, supporting overall cardiometabolic health. Studies show that it promotes healthy blood glucose regulation, reducing glycated hemoglobin (HbA1c) levels and supporting stable blood sugar control, making it valuable for research into glucose metabolism and insulin sensitivity. It also improves lipid profiles, reducing levels of triglycerides and non-high-density lipoprotein cholesterol, while lowering inflammatory markers such as high-sensitivity C-reactive protein (hsCRP) and supporting healthy blood pressure levels. These combined effects contribute to a reduced risk of cardiometabolic complications, making Retatrutide a key tool for research into metabolic syndrome and related conditions.

Retatrutide also shows promise in research related to obesity-associated comorbidities, offering potential benefits for conditions such as knee osteoarthritis, sleep apnea, and non-alcoholic fatty liver disease (NAFLD). In studies involving participants with obesity and knee osteoarthritis, Retatrutide-induced weight loss was associated with significant reductions in joint pain and improvements in physical function, with pain scores improving by an average of 76% in high-dose groups. For sleep apnea, the substantial weight loss achieved with Retatrutide translates to improved respiratory function and reduced symptoms, while its ability to reduce visceral and hepatic fat supports research into NAFLD and liver health.

As a research-only peptide, Retatrutide is intended exclusively for laboratory and preclinical research purposes, designed to support scientific investigation into metabolic pathways, weight regulation, and related physiological processes. It is not intended for human or veterinary diagnostic, therapeutic, or clinical use, and all handling and experimentation should be conducted by trained professionals in compliance with local laboratory regulations and ethical guidelines. The peptide is supplied in convenient vial formats, including common strengths such as 10mg, 20mg, and 60mg, to accommodate diverse research protocols and dosing requirements. Each vial is sealed to prevent contamination and preserve stability, with clear labeling detailing product specifications, batch information, and storage instructions for ease of use in laboratory settings.

In summary, Retatrutide stands as a groundbreaking research peptide that combines the power of three metabolic pathways into a single, innovative molecule. With its balanced triple-receptor activation, exceptional purity, stable formulation, and proven efficacy in research studies, it offers unparalleled opportunities for scientists and researchers to explore metabolic regulation, body composition management, and the treatment of obesity-related conditions. Whether investigating weight loss mechanisms, glucose metabolism, lipid regulation, or comorbidity management, Retatrutide provides a reliable, potent, and versatile tool that advances the frontiers of metabolic research and supports the development of future therapeutic insights.

Items	Specifications
CAS NO.	2381089-83-2
Product name	Retatrutide
Purity	99.9%
Packaging	10mg/vial, 10vials/box
Payment term	paypal ,bitcoin, usdt, usdc,alipay, bank transfer
MOQ	10 Vials
Shelf life	2 Years
Certificate	COA

Product Advantages

Our premium Retatrutide research peptide delivers a full range of professional, industry-leading advantages that make it the ideal choice for laboratory research procurement and official storefront listing. We strictly adhere to standardized GMP-level production specifications throughout the entire manufacturing process, ensuring every production step is completed in a dust-free, constant-temperature, and sterile purification workshop environment. This rigorous production environment effectively eliminates cross-contamination, microbial impurities, and unstable factors that may affect product activity, keeping the molecular structure of Retatrutide complete, stable, and highly active from production to final delivery. Every batch of our Retatrutide undergoes multi-layer professional testing including HPLC purity testing, molecular structural identification, heavy metal residual testing, and microbial safety inspection, maintaining ultra-high overall purity with zero ineffective impurities and zero residual pollutants, fully meeting international laboratory raw material standards and platform listing qualification requirements.

Our Retatrutide features professionally optimized molecular chain locking technology, which greatly enhances structural stability under normal transportation, storage, and laboratory operating conditions. The product comes in fine, uniform lyophilized powder form with no clumping, no discoloration, and no abnormal odor. It dissolves rapidly and completely in conventional laboratory solvents without producing sediment, suspended matter, or turbid substances after preparation. The finished solution remains clear and stable for a long time, which greatly improves the convenience of daily laboratory operation, shortens experimental preparation time, and ensures uniform concentration during research testing, effectively improving the accuracy and repeatability of all experimental data.

We possess large-scale standardized production capacity and complete raw material reserve systems, supporting long-term stable bulk supply, continuous batch replenishment, and zero out-of-stock risks. All batches maintain perfect consistency in appearance, purity, activity, and solubility, avoiding batch-to-batch differences that may interfere with experimental progress. Each batch of Retatrutide is accompanied by complete, formal test certificates, full inspection data records, and traceable source files, fully compliant with official platform review rules, laboratory filing standards, and formal commodity shelf management requirements.

Our Retatrutide boasts strong universal compatibility with all conventional metabolic research experiments, physiological pathway research, body composition related laboratory tests, and daily scientific research projects. It works stably with all common laboratory auxiliary reagents without component conflicts, adverse chemical reactions, or data interference, ensuring safe, smooth, and reliable experimental results every time. Adopting vacuum sealed independent packaging with thickened anti-pressure, moisture-proof, and light-proof outer protection, our products effectively resist oxidation, moisture erosion, and temperature fluctuations during long-distance transportation and long-term storage, extending the safe storage cycle and locking molecular activity for a longer period.

All our Retatrutide products are purely high-quality research raw materials, only used for scientific laboratory research and academic experimental analysis, fully compliant with platform access regulations, without any non-compliant descriptions or sensitive statements. Compared with ordinary peer products, our Retatrutide has higher purity, stronger stability, better solubility, stricter quality control, more complete documents, and more stable supply capacity. We also provide professional standardized after-sales service, including professional storage guidance, usage guidance, and complete docking materials for storefront review. It is the most reliable, safe, and compliant high-quality research-grade Retatrutide product for long-term laboratory procurement and formal e-commerce shelf sales.

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 1

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 2

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 3

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 4

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 5

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 6

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 7

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 8

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 9

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 10

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 11

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 12

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 13

Shop Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide-Detailed Image 14

ECHEMI Editorial Reference

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

Certificates

Basic Info

Product Name:

Retatrutide

Other Name:

Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

CAS No.:

2381089-83-2

InChIKeys:

MLOLQJNKXBNWFW-SAGGEDDASA-N

Molecular Weight:

EC Number:

200-001-8

Color/Form:

White lyophilized

Categories:

Polypeptide

Characteristics

Water Solubility:

Soluble in water (5mg/ml).

Storage Conditions:

-20°C

Critical Temperature & Pressure:

-20°C

Research

Class:

Triple agonist — GCGR, GIPR, GLP-1R

Status:

Investigational (Phase 3)

Mechanism:

Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

EC50 (Human GCGR):

5.79 nM

EC50 (Mouse GIPR):

0.191 nM

EC50 (Mouse GLP1R):

0.794 nM

EC50 (Mouse GCGR):

2.32 nM

EC50 (Human GLP1R):

0.775 nM

EC50 (Human GIPR):

0.0643 nM

Source:

Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

Clinical Development:

NCT04881760; NCT05882045; NCT06354660

References

ChEMBL:

DrugBank:

KEGG DRUG:

PubChem:

Literature:

NEJM: Jastreboff et al. (2023) — Phase 2 Trial; FDA Drugs@FDA

Disclaimer:

Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

See More Retatrutide Properties 

Seller Information

Business Type:
Trader

Main Products:
Tirzepatide,Retatrutide,Semaglutide,GHK-Cu

Location:
RM 701, UNIT 108, 7/F, TWR B NEW MANDARIN PLAZA 14 SCIENCE MUSEUM RD TSIM SHA TSUI HONG KONG

Year of Establishment:
2026

Inquiry History

7494 Inquiries

Country	Product	Purchase Quantity	Date Posted
Malaysia	Retatrutide	20 MG	Oct 28, 2026
United States	retatrutide	30 MG	Oct 28, 2026
Czech	Retatrutide	10 MG	Oct 28, 2026
Austria	retatrutide	30 MG	Oct 28, 2026
United States	Retatrutide	100 KG	Oct 28, 2026
Malta	Retatrutide	10 MT	Oct 28, 2026
United States	Retatrutide	600 MG	Oct 28, 2026
United States	Retatrutide	500 G	Oct 28, 2026
United States	Retatrutide	60 G	Oct 28, 2026
Croatia	Retatrutide	10 MG	Oct 28, 2026
United States	Retatrutide	200 MG	Oct 28, 2026
Sweden	Retatrutide	10 MG	Oct 28, 2026
United States	Retatrutide	1 G	Oct 27, 2026
United Kingdom	Retatrutide	10 MG	Oct 27, 2026
Lithuania	Retatrutide	30 MG	Oct 27, 2026
United States	Retatrutide	10 MG	Oct 27, 2026
Greece	Retatrutide	30 MG	Oct 27, 2026
Germany	Retatrutide	20 MG	Oct 27, 2026
Canada	Retatrutide	30 MG	Oct 27, 2026
United States	retatrutide	40 MG	Oct 27, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Retatrutide 98% white powder MT Maintain	Pharmaceutical Grade/98	$3072.01/G FOB	Maintain Biotech Co.Ltd	Inquiry
Retatrutide ML	Pharmaceutical Grade/99.4	$1/G FOB	MELOS BIOTECH (SHENZHEN) CO., LIMITED	Inquiry
Retatrutide///High quality purity 99% Retatrutide fast delivery CAS NO. 2381089-83-2	Medical level/99	$55-65/UNIT FOB	yuanfangshun	Inquiry
Retatrutide Lyophilized API Powder Bulk Wholesale Raw Material	Pharmacy Grade/95	$120-150/G FOB	XIUSHI BIOPHARMA (NANTONG) CO., LTD.	Inquiry
Retatrutide\|Purity 99+\|	Pharmaceutical Grade/99	$50/UNIT FOB	GY Peptides	Inquiry

Retatrutide CAS 2381089-83-2 99.9% 5mg 15mg 20mg 30mg 40mg Peptide

Product Details

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches

More from this Seller